Last 7 days
-1.6%
Last 30 days
-3.2%
Last 90 days
-29.4%
Trailing 12 Months
-29.9%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
UNH | 448.8B | 335.9B | -0.30% | -2.84% | 21.68 | 1.34 | 12.90% | 18.65% |
VEEV | 26.0B | 2.2B | -6.51% | -0.02% | 53.24 | 12.05 | 16.44% | 14.11% |
MID-CAP | ||||||||
CHNG | 9.0B | - | 11.88% | 31.28% | -116.8 | 2.57 | - | - |
TDOC | 3.7B | 2.5B | -11.99% | -32.20% | -0.53 | 1.5 | 15.22% | -2.18% |
OMCL | 3.3B | 1.3B | 24.63% | -32.85% | 583.74 | 2.54 | 14.48% | -92.74% |
SMALL-CAP | ||||||||
PHR | 1.6B | 280.9M | -4.19% | 67.00% | -9.15 | 5.74 | 31.74% | -49.07% |
MDRX | 1.4B | 837.2M | -3.25% | -29.92% | 22.47 | 1.63 | 3.88% | -92.18% |
NXGN | 1.0B | 653.2M | -10.02% | -15.43% | -381.88 | 1.55 | 9.53% | -264.03% |
CCRN | 920.4M | 2.6B | 15.69% | 53.16% | 5.9 | 0.35 | 23.61% | -10.67% |
SLP | 897.5M | 54.4M | 8.85% | -3.12% | 85.74 | 16.5 | 9.18% | -9.20% |
HSTM | 717.7M | 270.4M | -7.09% | 16.48% | 60.71 | 2.65 | 4.56% | 83.36% |
HCAT | 616.5M | 282.0M | -8.00% | -22.47% | -4.16 | 2.19 | 10.96% | -0.57% |
CPSI | 364.2M | 335.0M | -6.83% | -22.50% | 33.6 | 1.09 | 15.32% | -51.61% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Revenue | 0.9% | 837 | 830 | 820 | 811 | 806 |
Cost Of Revenue | -0.7% | 874 | 881 | 882 | 883 | 444 |
Gross Profit | 2.2% | 655 | 641 | 630 | 620 | 362 |
S&GA Expenses | 1.4% | 360 | 355 | 323 | 314 | 181 |
R&D Expenses | 1.3% | 201 | 198 | 196 | 194 | 117 |
EBITDA | -0.4% | 300 | 301 | 164 | 202 | - |
EBITDA Margin | -1.2% | 0.36* | 0.36* | 0.16* | 0.16* | - |
Earnings Before Taxes | -2.1% | 122 | 125 | 160 | 162 | -11.57 |
EBT Margin | 2.1% | 0.15* | 0.14* | 0.15* | 0.13* | - |
Interest Expenses | -21.4% | 9.00 | 11.00 | 12.00 | 13.00 | 16.00 |
Net Income | -2.7% | 61.00 | 62.00 | 148 | 134 | 775 |
Net Income Margin | -3.5% | 0.07* | 0.08* | 0.14* | 0.11* | - |
Free Cahsflow | -14.9% | 155 | 182 | -16.16 | -80.72 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Assets | -1.4% | 1,691 | 1,714 | 2,430 | 2,425 | 2,484 |
Current Assets | -2.2% | 811 | 829 | 1,541 | 761 | 805 |
Cash Equivalents | -1.5% | 493 | 500 | 83.00 | 133 | 142 |
Net PPE | -21.8% | 12.00 | 15.00 | 9.00 | 10.00 | 54.00 |
Goodwill | 0.0% | 524 | 524 | 520 | 507 | 974 |
Liabilities | -0.8% | 514 | 518 | 1,077 | 1,017 | 1,066 |
Current Liabilities | -1.3% | 253 | 256 | 647 | 547 | 567 |
Long Term Debt | - | 26.00 | - | - | - | - |
LT Debt, Non Current | 0.2% | 200 | 200 | 377 | 350 | 373 |
Shareholder's Equity | -1.6% | 1,177 | 1,196 | 1,353 | 1,408 | 1,419 |
Retained Earnings | 2.0% | 753 | 739 | 803 | 13.00 | 680 |
Additional Paid-In Capital | 0.0% | 1,924 | 1,924 | 1,922 | 1,962 | 1,952 |
Accumulated Depreciation | - | 323 | - | - | - | - |
Shares Outstanding | -1.4% | 109 | 111 | 115 | 116 | 123 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 |
Cashflow From Operations | -14.7% | 161 | 189 | -10.74 | -75.43 | -319 |
Share Based Compensation | 1.2% | 46.00 | 46.00 | 39.00 | 35.00 | 17.00 |
Cashflow From Investing | 1.7% | 646 | 635 | -37.38 | -12.17 | 1,625 |
Cashflow From Financing | 2.2% | -520 | -532 | -314 | -258 | -1,315 |
Buy Backs | 13.4% | 286 | 252 | 467 | 417 | 589 |
91.5%
58.1%
21.9%
Y-axis is the maximum loss one would have experienced if Allscripts Healthcare Solutions was unfortunately bought at previous high price.
-1.5%
-1.6%
-1.3%
21.0%
FIve years rolling returns for Allscripts Healthcare Solutions.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-05-23 | ROYCE & ASSOCIATES LP | added | 144 | 528,466 | 1,180,230 | 0.01% |
2023-05-23 | Brookfield Corp /ON/ | reduced | -36.77 | -514,359 | 452,013 | -% |
2023-05-23 | Front Row Advisors LLC | unchanged | - | -1,000 | 3,000 | -% |
2023-05-22 | PUTNAM INVESTMENTS LLC | added | 456 | 6,637,200 | 8,767,670 | 0.01% |
2023-05-22 | AMERIPRISE FINANCIAL INC | added | 15.19 | -1,469,470 | 8,464,530 | -% |
2023-05-18 | JPMORGAN CHASE & CO | reduced | -43.55 | -18,527,100 | 13,285,900 | -% |
2023-05-18 | NEW YORK STATE COMMON RETIREMENT FUND | reduced | -32.51 | -975,000 | 973,000 | -% |
2023-05-17 | Advisory Services Network, LLC | unchanged | - | -1,606 | 4,568 | -% |
2023-05-17 | Thrivent Financial for Lutherans | reduced | -3.39 | -564,000 | 1,413,000 | -% |
2023-05-17 | VIRGINIA RETIREMENT SYSTEMS ET AL | added | 110 | 1,119,570 | 1,896,300 | 0.02% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 10, 2023 | dimensional fund advisors lp | 8.5% | 9,277,320 | SC 13G/A | |
Feb 09, 2023 | vanguard group inc | 12.40% | 13,550,569 | SC 13G/A | |
Jan 26, 2023 | blackrock inc. | 19.1% | 20,902,942 | SC 13G/A | |
Jan 20, 2023 | blackrock inc. | 19.1% | 20,902,942 | SC 13G/A | |
Feb 09, 2022 | vanguard group inc | 10.82% | 13,268,135 | SC 13G/A | |
Feb 08, 2022 | dimensional fund advisors lp | 8.2% | 10,090,569 | SC 13G/A | |
Jan 28, 2022 | blackrock inc. | 19.5% | 23,846,502 | SC 13G/A | |
Apr 12, 2021 | wellington management group llp | 3.78% | 5,292,953 | SC 13G/A | |
Feb 12, 2021 | dimensional fund advisors lp | 6.9% | 10,939,535 | SC 13G/A | |
Feb 10, 2021 | vanguard group inc | 10.11% | 15,973,325 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | 4.48 -62.35% | 5.11 -57.06% | 6.43 -45.97% | 7.64 -35.80% | 9.54 -19.83% |
Current Inflation | 4.40 -63.03% | 5.00 -57.98% | 6.20 -47.90% | 7.30 -38.66% | 8.82 -25.88% |
Very High Inflation | 4.31 -63.78% | 4.85 -59.24% | 5.91 -50.34% | 6.87 -42.27% | 7.96 -33.11% |
Date Filed | Form Type | Document | |
---|---|---|---|
May 26, 2023 | 4 | Insider Trading | |
May 19, 2023 | 8-K | Current Report | |
May 11, 2023 | 4 | Insider Trading | |
May 11, 2023 | 4 | Insider Trading | |
May 11, 2023 | 4 | Insider Trading | |
May 11, 2023 | NT 10-Q | NT 10-Q | |
May 03, 2023 | 4 | Insider Trading | |
May 03, 2023 | 4 | Insider Trading | |
May 03, 2023 | 4 | Insider Trading | |
Apr 03, 2023 | 4 | Insider Trading |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-05-10 | Poulton Richard J. | sold (taxes) | -157,140 | 11.9 | -13,205 | ceo |
2023-05-10 | Vakharia Tejal | sold (taxes) | -37,711 | 11.9 | -3,169 | svp general counsel |
2023-05-10 | Hammond Lisa | sold (taxes) | -28,000 | 11.9 | -2,353 | svp & chief hr officer |
2023-05-02 | Langan Thomas | sold (taxes) | -22,999 | 12.15 | -1,893 | president and cco |
2023-05-02 | Jones Leah | sold (taxes) | -27,009 | 12.15 | -2,223 | chief financial officer |
2023-05-01 | Vakharia Tejal | sold (taxes) | -53,891 | 12.53 | -4,301 | svp general counsel |
2023-05-01 | Jones Leah | sold (taxes) | -86,031 | 12.53 | -6,866 | chief financial officer |
2023-05-01 | Langan Thomas | sold (taxes) | -117,206 | 12.53 | -9,354 | president and cco |
2023-04-01 | Vakharia Tejal | sold (taxes) | -33,447 | 13.05 | -2,563 | svp general counsel |
2023-04-01 | Langan Thomas | sold (taxes) | -193,218 | 13.05 | -14,806 | president and cco |
CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
---|---|---|---|---|
Sep. 30, 2022 | Sep. 30, 2021 | Sep. 30, 2022 | Sep. 30, 2021 | |
Revenue: | ||||
Revenue from contract with customers | $ 151,922 | $ 144,668 | $ 445,492 | $ 419,526 |
Cost of revenue: | ||||
Total cost of revenue | 68,486 | 75,028 | 209,093 | 218,550 |
Gross profit | 83,436 | 69,640 | 236,399 | 200,976 |
Selling, general and administrative expenses | 32,518 | 27,392 | 133,683 | 87,680 |
Research and development | 23,681 | 21,042 | 69,851 | 62,644 |
Asset impairment charges | 0 | 359 | 0 | 531 |
Amortization of intangible and acquisition-related assets | 2,236 | 2,363 | 6,648 | 7,090 |
Income from operations | 25,001 | 18,484 | 26,217 | 43,031 |
Interest expense | (1,246) | (3,617) | (5,269) | (9,709) |
Other income, net | 1,655 | 4,493 | 3,800 | 21,819 |
Gain on sale of businesses, net | 0 | 8,363 | 0 | 8,363 |
Equity in net loss income of unconsolidated investments | (617) | (257) | (1,222) | (321) |
Income from continuing operations before income taxes | 24,793 | 27,466 | 23,526 | 63,183 |
Income tax (provision) benefit | (13,868) | (7,190) | 9,132 | (12,464) |
Income from continuing operations, net of tax | 10,925 | 20,276 | 32,658 | 50,719 |
Income (loss) from discontinued operations | (434) | (6,187) | (9,252) | (6,545) |
Gain on sale of discontinued operations | 5,174 | 0 | 7,939 | 647 |
Income tax effect on discontinued operations | (1,137) | 2,091 | (57,986) | 2,342 |
Income (loss) from discontinued operations, net of tax | 3,603 | (4,096) | (59,299) | (3,556) |
Net income (loss) | $ 14,528 | $ 16,180 | $ (26,641) | $ 47,163 |
Basic | ||||
Continuing operations | $ 0.10 | $ 0.16 | $ 0.29 | $ 0.38 |
Discontinued operations | 0.03 | (0.03) | (0.52) | (0.03) |
Net earnings (loss) per Common Share | 0.13 | 0.13 | (0.23) | 0.35 |
Diluted | ||||
Continuing operations | 0.09 | 0.15 | 0.25 | 0.36 |
Discontinued operations | 0.03 | (0.03) | (0.44) | (0.03) |
Net earnings (loss) per Common Share | $ 0.12 | $ 0.12 | $ (0.19) | $ 0.33 |
Provider [Member] | ||||
Revenue: | ||||
Revenue from contract with customers | $ 122,811 | $ 118,179 | $ 360,415 | $ 345,253 |
Cost of revenue: | ||||
Total cost of revenue | 57,252 | 61,606 | 172,595 | 180,566 |
Payer & Life Sciences [Member] | ||||
Revenue: | ||||
Revenue from contract with customers | 29,111 | 26,489 | 85,077 | 74,273 |
Cost of revenue: | ||||
Total cost of revenue | $ 11,234 | $ 13,422 | $ 36,498 | $ 37,984 |
CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands | Sep. 30, 2022 | Dec. 31, 2021 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 492,597 | $ 132,517 |
Restricted cash | 1,307 | 1,308 |
Accounts receivable, net of allowance of $12,868 and $13,360 as of September 30, 2022 and December 31, 2021, respectively | 169,029 | 171,622 |
Contract assets, net of allowance of $564 and $576 as of September 30, 2022 and December 31, 2021, respectively | 65,453 | 63,429 |
Prepaid expenses and other current assets | 74,384 | 60,511 |
Assets held for sale | 8,000 | 331,955 |
Total current assets attributable to discontinued operations | 810,770 | 761,342 |
Fixed assets, net | 11,713 | 9,819 |
Software development costs, net | 78,103 | 74,688 |
Intangible assets, net | 145,255 | 149,690 |
Goodwill | 523,927 | 506,607 |
Deferred taxes, net | 6 | 0 |
Contract assets - long-term, net of allowance of $1,201 and $1,534 as of September 30, 2022 and December 31, 2021, respectively | 27,957 | 28,174 |
Right-of-use assets - operating leases | 14,520 | 18,324 |
Other assets | 78,408 | 83,429 |
Long-term assets attributable to discontinued operations | 0 | 793,156 |
Total assets | 1,690,659 | 2,425,229 |
Current liabilities: | ||
Accounts payable | 12,609 | 5,281 |
Accrued expenses | 82,917 | 54,518 |
Accrued compensation and benefits | 33,857 | 31,055 |
Deferred revenue | 98,930 | 120,748 |
Current operating lease liabilities | 6,166 | 6,133 |
Current liabilities attributable to discontinued operations | 18,612 | 329,347 |
Total current liabilities attributable to discontinued operations | 253,091 | 547,082 |
Long-term debt | 200,326 | 350,062 |
Deferred revenue | 3,060 | 1,839 |
Deferred taxes, net | 8,082 | 16,625 |
Long-term operating lease liabilities | 12,315 | 16,754 |
Other liabilities | 36,762 | 33,823 |
Long-term liabilities attributable to discontinued operations | 0 | 50,906 |
Total liabilities | 513,636 | 1,017,091 |
Commitments and contingencies | ||
Stockholders’ equity: | ||
Preferred stock: $0.01 par value, 1,000 shares authorized, no shares issued and outstanding as of September 30, 2022 and December 31, 2021 | 0 | 0 |
Common stock: $0.01 par value, 349,000 shares authorized as of September 30, 2022 and December 31, 2021; 279,600 and 109,260 shares issued and outstanding as of September 30, 2022, respectively; 276,705 and 116,114 shares issued and outstanding as of December 31, 2021, respectively | 2,794 | 2,766 |
Treasury stock: at cost, 170,340 and 160,591 shares as of September 30, 2022 and December 31, 2021, respectively | (1,498,836) | (1,321,805) |
Additional paid-in capital | 1,923,559 | 1,962,386 |
Retained earnings | 753,392 | 767,556 |
Accumulated other comprehensive loss | (3,886) | (2,765) |
Total stockholders’ equity | 1,177,023 | 1,408,138 |
Total liabilities and stockholders’ equity | $ 1,690,659 | $ 2,425,229 |